Rolitetracycline

Hypersensitivity; SLE; renal impairment; pregnancy, lactation; children ≤8 yr.

Myasthenia gravis; avoid direct sunlight; elderly; hepatic impairment. Serum monitoring is recommended.

GI disturbances; dry mouth; glossitis; tongue or teeth discoloration; stomatitis; dysphagia; oesophageal ulceration; oral candidiasis; vulvovaginitis; pruritus; enterocolitis; renal dysfunction; enamel hypoplasia; increased intracranial pressure with headache, visual disturbances and papilloedema (discontinue); bulging fontanelles in infants; hypersensitivity; nail discoloration; onycholysis; abnormal skin pigmentation. Shivering, peculiar taste sensation following injection; rapid IV inj may cause transient giddiness, hot flushes, reddening of the face and peripheral circulatory failure.
Potentially Fatal: Pseudomembranous colitis.

Diuretics, methoxyflurane and other potentially nephrotoxic drugs increase risk of nephrotoxicity. Increased risk of benign intracranial hypertension when used with retinoids. Decreases plasma concentrations of atovaquone. Ocular preparations containing thiomersal increase risk of ocular inflammation. May decrease efficacy of oral contraceptives.
Potentially Fatal: Increased toxic effects of ergot alkaloids and methotrexate.

Dairy and milk products.

May interfere with determination of urinary catecholamines or glucose.

Description:
Mechanism of Action: Rolitetracycline prevents the binding of aminoacyl transfer RNA and inhibits protein synthesis and hence cell growth. It has a broad spectrum of antimicrobial activity which includes chlamydias, rickettsias, spirochetes, many aerobic and anaerobic gram-negative and gram-positive pathogenic bacteria and some protozoa.
Pharmacokinetics:
Absorption: Reaches peak concentrations about 2-6 hr after IV admin.
Excretion: Half-life: about 5-8 hr. >50% eliminated via the urinary route.

Tetracyclin